SC3499 / Korea Kolmar, Dong-A - LARVOL DELTA

Rationally designed allosteric EGFR degrader SC3499 (IN-207375) selectively eliminates mutant EGFR and overcomes osimertinib resistance in non-small cell lung cancer (AACR 2026) - "Broad kinase profiling showed exceptional kinase selectivity, and global proteomic analysis confirmed selective degradation of mutant EGFR without affecting unrelated proteins or other cereblon (CRBN) substrates. These results support SC3499 as a promising, orally active, allosteric EGFR degrader capable of overcoming resistance to current EGFR-targeted therapies, including osimertinib, and providing durable antitumor responses in EGFR-mutant NSCLC."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CRBN • EGFR

Dong-A ST is set to strengthen its presence in global oncology research alongside its subsidiary Aptis by presenting new findings at the American Association for Cancer Research (AACR) 2026. [Google translation] (Korea IT Times) - "In the PARP7 inhibitor category, Dong-A ST will introduce novel candidates designed to simultaneously activate immune responses and suppress tumor growth. Preclinical results showed that some candidates demonstrated significant efficacy as monotherapy and achieved complete remission when combined with anti-PD-1 antibodies or conventional chemotherapy, highlighting strong synergistic potential....SC3613 selectively degrades mutant EGFR, inducing both tumor suppression and immune activation, while showing reduced skin toxicity and improved tolerability compared to existing therapies. Another candidate, SC3499, maintained activity against mutations resistant to osimertinib and demonstrated efficacy with once-daily oral dosing."

Preclinical • Non Small Cell Lung Cancer